Submitting OIG:
Report Description:
For a covered outpatient drug to be eligible for Federal reimbursement under the Medicaid program's drug rebate requirements, manufacturers must pay rebates to the States for the drugs. However, a prior OIG review found that States did not always invoice and collect all rebates due for drugs administered by physicians.
Our objective was to determine whether New Jersey complied with Federal Medicaid requirements for invoicing manufacturers for rebates for physician-administered drugs.
Date Issued:
Thursday, May 9, 2019
Agency Reviewed / Investigated:
Submitting OIG-Specific Report Number:
A-02-16-01012
Component, if applicable:
Centers for Medicare & Medicaid Services
Location(s):
Agency-Wide
Type of Report:
Audit
Questioned Costs:
$8,139,939
Number of Recommendations:
7
View Document:
Attachment | Size |
---|---|
21601012.pdf | 1.01 MB |
Additional Details Link: